demonstrated that inhibiting CXCR2 signaling, which is predominantly upregulated in neutrophils and myeloid‐derived suppressor cells (MDSCs), profoundly suppresses metastasis and enhances the efficacy of immunotherapy in PDAC.[176] Notably, tumors with low TILs often harbor higher proportions of TANs and show resistance to ICIs, while disrupting key signaling pathways that reduce TAN infiltration, such as CXCL1 or CXCL5/CXCR2 signaling, increases CD8+ PD‐1+ T cell levels, and improves tumor sensitivity to ICI therapy.[177, 178]. Here, CXCR2 is linked to neoplasm.